MP
Therapeutic Areas
Novocure Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Optune / EF-31 (METIS) | Brain Metastases from NSCLC | Phase 3 |
| Optune / EF-32 (TRIDENT) | Newly Diagnosed Glioblastoma | Phase 3 |
| TTFields / LUNAR | Metastatic NSCLC | Phase 3 |
| TTFields / INNOVATE-3 | Platinum-Resistant Ovarian Cancer | Phase 3 |
| TTFields / PANOVA-3 | Locally Advanced Pancreatic Cancer | Phase 3 |
| TTFields | Gastric Cancer | Pilot |
Leadership Team at Novocure
FL
Frank Leonard
Chief Executive Officer
WF
William F. Doyle
Executive Chairman
CB
Christoph Brackmann
Chief Financial Officer
MP
Mukund Paravasthu
Chief Operating Officer
UW
Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
BB
Barak Ben-Arye
General Counsel
PY
Professor Yoram Palti
Founder